IL174375A0 - Novel heterocyclic compounds as hsp90-inhibitors - Google Patents
Novel heterocyclic compounds as hsp90-inhibitorsInfo
- Publication number
- IL174375A0 IL174375A0 IL174375A IL17437506A IL174375A0 IL 174375 A0 IL174375 A0 IL 174375A0 IL 174375 A IL174375 A IL 174375A IL 17437506 A IL17437506 A IL 17437506A IL 174375 A0 IL174375 A0 IL 174375A0
- Authority
- IL
- Israel
- Prior art keywords
- hsp90
- inhibitors
- heterocyclic compounds
- novel heterocyclic
- novel
- Prior art date
Links
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50413503P | 2003-09-18 | 2003-09-18 | |
| US59146704P | 2004-07-26 | 2004-07-26 | |
| PCT/US2004/031248 WO2005028434A2 (en) | 2003-09-18 | 2004-09-20 | Novel heterocyclic compounds as hsp90-inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL174375A0 true IL174375A0 (en) | 2006-08-01 |
Family
ID=34381103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL174375A IL174375A0 (en) | 2003-09-18 | 2006-03-16 | Novel heterocyclic compounds as hsp90-inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (8) | US7138401B2 (2) |
| EP (2) | EP1670802A4 (2) |
| JP (1) | JP2007505933A (2) |
| KR (1) | KR20060070572A (2) |
| CN (1) | CN101906106A (2) |
| AU (2) | AU2004274507B2 (2) |
| BR (1) | BRPI0414533A (2) |
| CA (1) | CA2539548A1 (2) |
| EA (1) | EA010160B1 (2) |
| IL (1) | IL174375A0 (2) |
| MX (1) | MXPA06002997A (2) |
| NO (1) | NO20061396L (2) |
| NZ (1) | NZ546611A (2) |
| WO (1) | WO2005028434A2 (2) |
Families Citing this family (190)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6992188B1 (en) * | 1995-12-08 | 2006-01-31 | Pfizer, Inc. | Substituted heterocyclic derivatives |
| US7439359B2 (en) * | 2000-11-02 | 2008-10-21 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to hsp90 |
| WO2003000187A2 (en) * | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof |
| WO2003037860A2 (en) * | 2001-10-30 | 2003-05-08 | Conforma Therapeutics Corporation | Purine analogs having hsp90-inhibiting activity |
| US20070129334A1 (en) * | 2001-10-30 | 2007-06-07 | Conforma Therapeutics Corporation | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 |
| MXPA06002997A (es) * | 2003-09-18 | 2007-02-08 | Conforma Therapeutics Corp | Novedosos compuestos heterociclicos como inhibidores- hsp90. |
| WO2006050333A2 (en) * | 2004-11-02 | 2006-05-11 | The Regents Of The University Of California | Methods and compositions for modulating apoptosis |
| KR20070085677A (ko) * | 2004-11-02 | 2007-08-27 | 콘포마 세러퓨틱스 코포레이션 | 만성 림프성 백혈병의 치료 방법 및 치료 조성물 |
| US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US8212012B2 (en) * | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| AU2006230447A1 (en) * | 2005-03-30 | 2006-10-05 | Conforma Therapeutics Corporation | Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors |
| JP5154406B2 (ja) * | 2005-04-13 | 2013-02-27 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| BRPI0609309A2 (pt) * | 2005-04-14 | 2010-03-09 | Novartis Vaccines & Diagnostic | 2-amino-quinazolin-5-onas como inibidores hsp90 com utilidade no tratamento de doenças proliferativas |
| US20060258691A1 (en) * | 2005-05-13 | 2006-11-16 | Joseph Barbosa | Methods and compositions for improving cognition |
| US7932257B2 (en) * | 2005-07-22 | 2011-04-26 | Sunesis Pharmaceuticals, Inc. | Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors |
| EP1926734A1 (en) | 2005-08-22 | 2008-06-04 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
| CN101304748A (zh) | 2005-08-22 | 2008-11-12 | 加利福尼亚大学董事会 | Tlr激动剂 |
| CA2619972A1 (en) * | 2005-08-24 | 2007-03-01 | Lexicon Pharmaceuticals, Inc. | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use |
| WO2007035963A2 (en) * | 2005-09-23 | 2007-03-29 | Conforma Therapeutics Corporation | Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors |
| EP1954286A2 (en) * | 2005-11-10 | 2008-08-13 | SmithKline Beecham Corporation | Inhibitors of akt activity |
| EP1948185A4 (en) * | 2005-11-10 | 2010-04-21 | Glaxosmithkline Llc | INHIBITORS OF AKT ACTIVITY |
| WO2007075572A2 (en) * | 2005-12-22 | 2007-07-05 | Conforma Therapeutics Corporation | Orally active purine-based inhibitors of heat shock protein 90 |
| EP2012791A4 (en) * | 2006-02-07 | 2010-09-22 | Conforma Therapeutics Corp | 7,9-DIHYDRO-PURIN-8-ONE AND RELATED ANALOGUES AS INHIBITORS OF HSP90 |
| US8658633B2 (en) * | 2006-02-16 | 2014-02-25 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
| WO2007134298A2 (en) * | 2006-05-12 | 2007-11-22 | Myriad Genetics, Inc. | Therapeutic compounds and their use in cancer |
| EP2700638A1 (en) * | 2006-05-31 | 2014-02-26 | The Regents Of the University of California | Purine analogs |
| WO2008005937A2 (en) | 2006-06-30 | 2008-01-10 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibiton of hsp90 |
| US20080009508A1 (en) * | 2006-07-10 | 2008-01-10 | Lucie Szucova | 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin |
| DE602006003651D1 (de) * | 2006-08-03 | 2008-12-24 | Cellzome Ag | Verfahren zur Identifizierung von Molekülen die mit PI3K interagieren und Verfahren zur Reinigung von PI3K |
| DK2065388T3 (da) * | 2006-09-19 | 2012-01-09 | Daiichi Sankyo Co Ltd | Pyrazolopyrimidinderivat |
| WO2008045529A1 (en) * | 2006-10-12 | 2008-04-17 | Serenex, Inc. | Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases |
| CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| FR2907453B1 (fr) * | 2006-10-24 | 2008-12-26 | Sanofi Aventis Sa | Nouveaux derives du fluorene,compositions les contenant et utilisation |
| GB0622084D0 (en) * | 2006-11-06 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of HSP90 |
| CA2676665A1 (en) * | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | Modulators of mitotic kinases |
| AU2008211729A1 (en) * | 2007-02-01 | 2008-08-07 | Astrazeneca Ab | 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors |
| CN101790380B (zh) | 2007-02-07 | 2013-07-10 | 加利福尼亚大学董事会 | 合成tlr激动剂的缀合物及其应用 |
| KR101313804B1 (ko) * | 2007-03-20 | 2013-10-01 | 쿠리스 인코퍼레이션 | Ｈｓｐ９０ 억제제로서의 융합된 아미노 피리딘 |
| JP5454943B2 (ja) | 2007-04-12 | 2014-03-26 | ジョイアント ファーマスーティカルズ、インク． | 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体 |
| US8143265B2 (en) * | 2007-04-16 | 2012-03-27 | Meharry Medical College | Method of treating atherosclerosis |
| US7960353B2 (en) * | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| DE102007028521A1 (de) * | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | Indazolamidderivate |
| US8119616B2 (en) * | 2007-09-10 | 2012-02-21 | Curis, Inc. | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety |
| JP2011501731A (ja) * | 2007-09-10 | 2011-01-13 | ユニバーシティ オブ マサチューセッツ | ミトコンドリア標的化抗腫瘍剤 |
| GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| WO2009086170A1 (en) | 2007-12-21 | 2009-07-09 | Joyant Pharmaceuticals, Inc. | Diazonamide analogs with improved solubility |
| US8895701B2 (en) * | 2008-01-05 | 2014-11-25 | Sloan-Kettering Institute For Cancer Research | Peptide-conjugated oligonucleotide therapeutic and method of making and using same |
| EA201001264A1 (ru) * | 2008-02-07 | 2011-04-29 | Дзе Регентс Оф Дзе Юниверсити Оф Калифорния | Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7 |
| US8190543B2 (en) * | 2008-03-08 | 2012-05-29 | Tokyo Electron Limited | Autonomous biologically based learning tool |
| WO2009114470A2 (en) * | 2008-03-10 | 2009-09-17 | Curis, Inc. | Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety |
| EP2252293B1 (en) | 2008-03-14 | 2018-06-27 | Intellikine, LLC | Kinase inhibitors and methods of use |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| CN102014632B (zh) | 2008-04-29 | 2014-05-28 | 焦阳特制药股份有限公司 | 吲哚啉抗癌剂 |
| LT5623B (lt) | 2008-04-30 | 2010-01-25 | Biotechnologijos Institutas, , | 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti |
| CN102098918A (zh) * | 2008-05-13 | 2011-06-15 | 帕纳德制药公司 | 用于治疗癌症和神经退行性疾病的生物活性化合物 |
| US8153619B2 (en) | 2008-05-22 | 2012-04-10 | Joyant Pharmaceuticals, Inc. | Diazonamide analogs |
| BRPI0915231A2 (pt) | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
| WO2010014617A1 (en) * | 2008-07-28 | 2010-02-04 | University Of Kansas | Heat shock protein 90 inhibitor dosing methods |
| GB0819102D0 (en) * | 2008-10-17 | 2008-11-26 | Chroma Therapeutics Ltd | Pyrrolo-pyrimidine compounds |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| AU2009322836B2 (en) * | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP2387316A4 (en) * | 2009-01-16 | 2012-06-13 | Curis Inc | CONDENSED AMINOPYRIDINE FOR THE TREATMENT OF BRAIN TUMORS |
| WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| KR20110117705A (ko) * | 2009-02-11 | 2011-10-27 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 톨-유사 수용체 조정제 및 질병의 치료 |
| BRPI1008000A2 (pt) | 2009-02-25 | 2016-02-23 | Daiichi Sankyo Co Ltd | composto, hidrobrometo, hidrocloreto, metanossulfonato, etano-1, 2-dissulfonato, inibidor de hsp90, agente para inibir a atividade de atpase de hsp90, agente para inibir a ligação de hsp90 em atp, medicamento, agente anticâncer, composição farmacêutica, método para tratar câncer, e, uso de um composto. |
| EP2770327B1 (en) * | 2009-03-30 | 2017-06-14 | Nordic Bioscience A/S | Fibrosis biomarker assay |
| WO2010117425A1 (en) * | 2009-03-31 | 2010-10-14 | Biogen Idec Ma Inc. | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
| KR101763656B1 (ko) | 2009-06-29 | 2017-08-01 | 인사이트 홀딩스 코포레이션 | Ｐｉ3ｋ 저해물질로서의 피리미디논 |
| PT2452940E (pt) * | 2009-07-10 | 2015-02-27 | Taiho Pharmaceutical Co Ltd | Composto azabiciclo e seu sal |
| NZ598220A (en) | 2009-08-17 | 2014-02-28 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| WO2011041593A1 (en) * | 2009-09-30 | 2011-04-07 | University Of Kansas | Novobiocin analogues and treatment of polycystic kidney disease |
| JP5941407B2 (ja) | 2009-10-07 | 2016-06-29 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０阻害剤 |
| US8551955B2 (en) | 2009-10-28 | 2013-10-08 | Joyant Pharmaceuticals, Inc. | Dimeric Smac mimetics |
| US20110130711A1 (en) * | 2009-11-19 | 2011-06-02 | Follica, Inc. | Hair growth treatment |
| TW201130842A (en) * | 2009-12-18 | 2011-09-16 | Incyte Corp | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
| US8759359B2 (en) * | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| CN102762551A (zh) | 2009-12-21 | 2012-10-31 | 拜尔农作物科学股份公司 | 噻吩基吡(嘧)啶基吡唑及其用于防治植物致病菌的用途 |
| EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
| US9050319B2 (en) | 2010-04-30 | 2015-06-09 | Telormedix, Sa | Phospholipid drug analogs |
| AU2011247358B2 (en) | 2010-04-30 | 2014-10-30 | Urogen Pharma Ltd. | Phospholipid drug analogs |
| US9290499B2 (en) | 2010-05-19 | 2016-03-22 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
| WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| EP2810945A1 (en) | 2010-08-23 | 2014-12-10 | Daiichi Sankyo Company, Limited | Dihydrochloride salt of a tricyclic pyrazolopyrimidine derivative |
| TW201213334A (en) | 2010-08-23 | 2012-04-01 | Daiichi Sankyo Co Ltd | Crystal forms of free form of tricyclic pyrazolopyrimidine derivative |
| WO2012064744A2 (en) | 2010-11-08 | 2012-05-18 | Lycera Corporation | Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease |
| WO2012083181A1 (en) * | 2010-12-16 | 2012-06-21 | Indiana University Research And Technology Corporation | Alpha helix mimetics and methods for using |
| TW201500358A (zh) | 2010-12-16 | 2015-01-01 | 赫夫門羅氏藥廠股份有限公司 | 三環ｐｉ３ｋ抑制劑化合物及其使用方法 |
| EP3660016A1 (en) | 2010-12-20 | 2020-06-03 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| US8362023B2 (en) | 2011-01-19 | 2013-01-29 | Hoffmann-La Roche Inc. | Pyrazolo pyrimidines |
| RU2013138835A (ru) | 2011-02-09 | 2015-03-20 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения в качестве ингибиторов pi3 киназы |
| US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| JP6266506B2 (ja) | 2011-04-05 | 2018-01-24 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０阻害物質 |
| CN103596955B (zh) | 2011-04-05 | 2016-11-16 | 索隆-基特林癌症研究协会 | Hsp90抑制剂 |
| CN103582645B (zh) | 2011-04-22 | 2016-02-24 | 焦阳特制药股份有限公司 | 二氢氧茚吲哚类似物 |
| JP2014515368A (ja) | 2011-05-26 | 2014-06-30 | 第一三共株式会社 | プロテインキナーゼ阻害剤としての複素環化合物 |
| US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
| ITTO20110652A1 (it) * | 2011-07-20 | 2013-01-21 | Medestea Res & Production S P A | Composto derivato dall'adenina avente azione immuno-modulante, antinfiammatoria e antidolorifica |
| PT3513793T (pt) | 2011-09-02 | 2021-05-10 | Incyte Holdings Corp | Heterociclilaminas como inibidores de pi3k |
| MX2014004086A (es) | 2011-10-03 | 2014-09-22 | Univ North Carolina | Compuestos de pirrolopirimidina para el tratamiento del cancer. |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| JP6242868B2 (ja) | 2012-05-08 | 2017-12-06 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物 |
| WO2013169704A2 (en) | 2012-05-08 | 2013-11-14 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| CA2912048A1 (en) * | 2012-05-15 | 2013-11-21 | Calasia Pharmaceuticals, Inc. | Pyrimidine diamine derivatives as inhibitors of cytosolic hsp90 |
| AU2013266438B2 (en) | 2012-05-22 | 2017-09-07 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
| RS58514B1 (sr) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| WO2014055624A1 (en) | 2012-10-02 | 2014-04-10 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Methods relating to dna-sensing pathway related conditions |
| JP2015531395A (ja) | 2012-10-04 | 2015-11-02 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤 |
| CN103724269B (zh) * | 2012-10-11 | 2016-12-21 | 中国科学院上海药物研究所 | 苯基1,2-异噁唑或苯基1,2-吡唑类化合物及其用途 |
| EP2909211A4 (en) | 2012-10-17 | 2016-06-22 | Univ North Carolina | PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
| EP2925752A4 (en) | 2012-11-27 | 2016-06-01 | Univ North Carolina | PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
| SI2941432T1 (en) | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US8957078B2 (en) | 2013-03-15 | 2015-02-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2014145576A2 (en) | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| EP2970288A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2972394A4 (en) | 2013-03-15 | 2016-11-02 | Sloan Kettering Inst Cancer | HSP90-DESIGNING AND THERAPY |
| WO2014153509A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
| SG11201601542SA (en) | 2013-08-16 | 2016-04-28 | Sloan Kettering Inst Cancer | Selective grp94 inhibitors and uses thereof |
| PT3077397T (pt) | 2013-12-06 | 2020-01-22 | Vertex Pharma | Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo |
| US9783511B2 (en) | 2013-12-20 | 2017-10-10 | Lycera Corporation | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease |
| US9809561B2 (en) | 2013-12-20 | 2017-11-07 | Merck Sharp & Dohme Corp. | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
| WO2015095788A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| JP2017507950A (ja) | 2014-02-27 | 2017-03-23 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法 |
| ES2548927B1 (es) * | 2014-03-21 | 2016-08-11 | Universidad De Granada | Derivados de purina como inhibidores de Dapk-1 |
| US9555031B2 (en) * | 2014-04-11 | 2017-01-31 | The University Of North Carolina At Chapel Hill | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity |
| EP3140291A4 (en) | 2014-05-05 | 2018-01-10 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| JP6523337B2 (ja) | 2014-05-05 | 2019-05-29 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物 |
| MX373102B (es) | 2014-06-05 | 2020-04-17 | Vertex Pharma | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo. |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
| MX387627B (es) | 2014-09-17 | 2025-03-18 | Memorial Sloan Kettering Cancer Center | Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| KR101713638B1 (ko) * | 2014-11-18 | 2017-03-08 | 한국과학기술연구원 | 신규한 피롤로 피리미딘 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| CA2975997A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof |
| TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| SG10201907576SA (en) | 2015-02-27 | 2019-09-27 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
| US10421751B2 (en) | 2015-05-05 | 2019-09-24 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| AU2016276947A1 (en) | 2015-06-11 | 2017-12-14 | Lycera Corporation | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| CA3217238A1 (en) | 2015-07-20 | 2017-01-26 | Genzyme Corporation | Colony stimulating factor-1 receptor (csf-1r) inhibitors |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| US10344000B2 (en) | 2015-10-27 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
| EP3368535B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
| JP2018535958A (ja) | 2015-10-27 | 2018-12-06 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ＲＯＲγＴ阻害薬としての置換インダゾール化合物及びその使用 |
| US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
| US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
| KR101896616B1 (ko) * | 2016-10-11 | 2018-09-07 | 한국과학기술연구원 | 2-아미노 퓨린 유도체 화합물, 이를 제조하는 방법, 및 이의 용도 |
| KR102053933B1 (ko) * | 2016-10-26 | 2019-12-11 | 울산과학기술원 | Trap1 저해제로서 유용한 화합물 및 이를 포함하는 항암용 조성물 |
| LT3483164T (lt) | 2017-03-20 | 2020-05-11 | Forma Therapeutics, Inc. | Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| US10472361B2 (en) * | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| CN107857763A (zh) * | 2017-11-28 | 2018-03-30 | 江苏杏睿生物科技有限公司 | 一种邻硝基芳酰化衍生物类化合物、制备方法及其应用 |
| FR3075794A1 (fr) * | 2017-12-21 | 2019-06-28 | Galderma Research & Development | Nouveaux composes inhibiteurs de mtor |
| FR3075795A1 (fr) | 2017-12-21 | 2019-06-28 | Galderma Research & Development | Nouveaux composes inhibiteurs de mtor |
| EP4566612A3 (en) | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| AU2019262579B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Salts of an FGFR inhibitor |
| HRP20241288T1 (hr) | 2018-05-04 | 2024-12-06 | Incyte Corporation | Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju |
| CA3102279A1 (en) | 2018-06-01 | 2019-12-05 | Cornell University | Combination therapy for pi3k-associated disease or disorder |
| SG11202011680YA (en) | 2018-06-01 | 2020-12-30 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| EP3852791B1 (en) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Activating pyruvate kinase r |
| EP3853206B1 (en) | 2018-09-19 | 2024-04-10 | Novo Nordisk Health Care AG | Treating sickle cell disease with a pyruvate kinase r activating compound |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| HRP20251148T1 (hr) | 2019-09-19 | 2025-11-21 | Novo Nordisk Health Care Ag | Pripravci koji aktiviraju piruvat-kinazu r (pkr) |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7832891B2 (ja) | 2019-12-04 | 2026-03-18 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR102516260B1 (ko) * | 2020-07-10 | 2023-03-31 | 울산과학기술원 | Trap1 선택적 억제제로서의 화합물 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| JP2024500919A (ja) | 2020-12-23 | 2024-01-10 | ジェンザイム・コーポレーション | 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN115925724B (zh) * | 2022-11-16 | 2024-09-06 | 成都中医药大学 | 一种具有抗炎作用的腺嘌呤类化合物及其制备方法与应用 |
| CN116332940B (zh) * | 2023-02-14 | 2024-09-13 | 广西民族大学 | 一种7-脱氮嘌呤衍生物及其制备方法和应用 |
Family Cites Families (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB884151A (en) | 1957-12-06 | 1961-12-06 | Ciba Ltd | New pyrazolo-pyrimidines substituted in the pyrazole nucleus, and process for their manufacture |
| IL64501A (en) | 1980-12-22 | 1985-07-31 | Astra Laekemedel Ab | 9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use |
| US4699877A (en) * | 1982-11-04 | 1987-10-13 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
| US5098906A (en) | 1983-10-31 | 1992-03-24 | Warner-Lambert Company | Purine derivatives |
| US4806642A (en) | 1984-10-05 | 1989-02-21 | Warner-Lambert Company | Purine derivatives |
| US4921859A (en) * | 1983-10-31 | 1990-05-01 | Warner-Lambert Company | Purine derivatives |
| US4547573A (en) * | 1983-12-02 | 1985-10-15 | Ici Pharma | Process for preparing cephalosporin derivatives |
| EP0151528B1 (en) * | 1984-02-02 | 1990-07-04 | Merck & Co. Inc. | 5-(amino or substituted amino)-1,2,3-triazoles |
| US4748177A (en) | 1984-03-26 | 1988-05-31 | Warner-Lambert Company | Guanine derivatives |
| US4617304A (en) | 1984-04-10 | 1986-10-14 | Merck & Co., Inc. | Purine derivatives |
| IT1196261B (it) * | 1984-09-20 | 1988-11-16 | Pierrel Spa | Derivati nucleosidici e purinici 8-sostituiti |
| US4772606A (en) * | 1985-08-22 | 1988-09-20 | Warner-Lambert Company | Purine derivatives |
| IL76546A (en) | 1984-10-12 | 1988-12-30 | Warner Lambert Co | 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them |
| ZA857647B (en) * | 1984-10-12 | 1986-05-28 | Warner Lambert Co | Purine derivatives |
| JO1406B1 (en) | 1984-11-02 | 1986-11-30 | سميث كلاين اند فرينش لابوراتوريز ليمتد | Chemical compounds |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| WO1986005519A1 (en) | 1985-03-15 | 1986-09-25 | James Summerton | Polynucleotide assay reagent and method |
| IL78643A0 (en) | 1985-05-02 | 1986-08-31 | Wellcome Found | Purine derivatives,their preparation and pharmaceutical compositions containing them |
| GB8515934D0 (en) | 1985-06-24 | 1985-07-24 | Janssen Pharmaceutica Nv | (4-piperidinomethyl and-hetero)purines |
| US4918162A (en) * | 1986-05-06 | 1990-04-17 | The Regents Of The University Of California | Assays and antibodies for N-MYC proteins |
| DE3623099C3 (de) * | 1986-07-09 | 1998-08-13 | Spoetzl Markus Dipl Ing Fh | Blasformmaschine |
| US5002950A (en) * | 1986-10-24 | 1991-03-26 | Warner-Lambert Co. | 7-deazaguanines as immunomodulators |
| US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| US5204353A (en) | 1987-04-07 | 1993-04-20 | Ciba-Geigy Corporation | 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith |
| JPH0821101B2 (ja) | 1987-07-21 | 1996-03-04 | 三洋電機株式会社 | 硬貨選別装置 |
| SE8801729D0 (sv) | 1988-05-06 | 1988-05-06 | Astra Ab | Purine derivatives for use in therapy |
| US4923885A (en) * | 1988-08-19 | 1990-05-08 | Merck & Co., Inc. | 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents |
| EP0363320A3 (de) * | 1988-10-06 | 1991-11-21 | Ciba-Geigy Ag | Substituierte 9H-Purine |
| US5332744A (en) | 1989-05-30 | 1994-07-26 | Merck & Co., Inc. | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists |
| EP0465297B1 (en) | 1990-07-04 | 1996-01-31 | Merrell Dow Pharmaceuticals Inc. | 9-Purinyl phosphonic acid derivatives |
| GB9020931D0 (en) | 1990-09-26 | 1990-11-07 | Wellcome Found | Heterocyclic compounds |
| DK0502690T3 (da) | 1991-03-05 | 2000-05-22 | Ajinomoto Kk | Cyclopropanderivat |
| US5939420A (en) | 1991-04-08 | 1999-08-17 | Duquesne University Of The Holy Ghost | Pyrrolo 2,3d!derivatives |
| WO1992021032A1 (en) * | 1991-05-24 | 1992-11-26 | The Regents Of The University Of California | Methods for the detection of bcr-abl and abnormal abl proteins in leukemia patients |
| US6025126A (en) * | 1991-10-28 | 2000-02-15 | Arch Development Corporation | Methods and compositions for the detection of chromosomal aberrations |
| CA2093403C (en) | 1992-04-08 | 1999-08-10 | Fumio Suzuki | Therapeutic agent for parkinson's disease |
| JPH0680670A (ja) | 1992-09-03 | 1994-03-22 | Ajinomoto Co Inc | シクロプロパン誘導体及びその製造法 |
| US6005107A (en) | 1992-12-23 | 1999-12-21 | Biochem Pharma, Inc. | Antiviral compounds |
| US6444656B1 (en) * | 1992-12-23 | 2002-09-03 | Biochem Pharma, Inc. | Antiviral phosphonate nucleotides |
| GB9226879D0 (en) | 1992-12-23 | 1993-02-17 | Iaf Biochem Int | Anti-viral compounds |
| US5744492A (en) | 1993-09-17 | 1998-04-28 | United States Of America | Method for inhibiting angiogenesis |
| US5602156A (en) | 1993-09-17 | 1997-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | Method for inhibiting metalloproteinase expression |
| GB9402161D0 (en) * | 1994-02-04 | 1994-03-30 | Wellcome Found | Chloropyrimidine intermediates |
| JP3769737B2 (ja) | 1994-03-30 | 2006-04-26 | 味の素株式会社 | シクロプロパン誘導体及びその製造法 |
| US5932566A (en) * | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
| US5994361A (en) | 1994-06-22 | 1999-11-30 | Biochem Pharma | Substituted purinyl derivatives with immunomodulating activity |
| US5525606A (en) * | 1994-08-01 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines |
| JPH0841035A (ja) | 1994-08-05 | 1996-02-13 | Ajinomoto Co Inc | シクロプロパン誘導体及びその製造法 |
| US5846749A (en) * | 1994-10-12 | 1998-12-08 | The Regents Of The University Of California | Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination |
| JPH08208687A (ja) | 1994-11-25 | 1996-08-13 | Sankyo Co Ltd | グリセリルオリゴヌクレオチド |
| US5656629A (en) | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
| US6177460B1 (en) * | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
| JPH0920776A (ja) | 1995-06-30 | 1997-01-21 | Nippon Paper Ind Co Ltd | 新規なプリンヌクレオシド誘導体、その製造方法及びその誘導体を有効成分とする抗ウイルス剤 |
| JPH09169758A (ja) | 1995-10-18 | 1997-06-30 | Nippon Paper Ind Co Ltd | 新規なプリンヌクレオシド誘導体、その製造方法、及びそれを用いた抗ウイルス剤 |
| JPH1025294A (ja) | 1996-03-26 | 1998-01-27 | Akira Matsuda | 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤 |
| ES2232871T3 (es) | 1996-07-03 | 2005-06-01 | Sumitomo Pharmaceuticals Company, Limited | Nuevos derivados de purina. |
| US6723727B1 (en) | 1996-12-20 | 2004-04-20 | Hoechst Aktiengesellschaft | Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them |
| US6284748B1 (en) | 1997-03-07 | 2001-09-04 | Metabasis Therapeutics, Inc. | Purine inhibitors of fructose 1,6-bisphosphatase |
| US5861503A (en) | 1997-04-30 | 1999-01-19 | The Regents Of The University Of California | Process for producing 8-fluoropurines |
| CA2287387C (en) | 1997-05-14 | 2010-02-16 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for destruction of selected proteins |
| PL337888A1 (en) | 1997-07-03 | 2000-09-11 | Du Pont Pharm Co | Imidazoprimidines and imidazopyridines for use in treating neurological disorders |
| EP1017394B1 (en) | 1997-07-12 | 2005-12-07 | Cancer Research Technology Limited | Cyclin dependent kinase inhibiting purine derivatives |
| GB9717849D0 (en) | 1997-08-23 | 1997-10-29 | Seal Sands Chemicals Limited | Preparation of pyridene derivatives |
| AUPO912997A0 (en) | 1997-09-11 | 1997-10-02 | Commonwealth Scientific And Industrial Research Organisation | Antiviral agents |
| US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
| CN1130363C (zh) | 1997-11-12 | 2003-12-10 | 三菱化学株式会社 | 嘌呤衍生物以及含有其作为有效成分的药物 |
| TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| AU3378599A (en) | 1998-04-03 | 1999-10-25 | University Of Pittsburgh | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke |
| US5985060A (en) | 1998-07-25 | 1999-11-16 | Breed Automotive Technology, Inc. | Gas generant compositions containing guanidines |
| SI20022A (sl) | 1998-07-29 | 2000-02-29 | Kemijski inštitut | Alkilno substituirani purinovi derivati in njihova priprava |
| JP2000072773A (ja) | 1998-08-28 | 2000-03-07 | Zeria Pharmaceut Co Ltd | プリン誘導体 |
| US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
| ES2333845T3 (es) * | 1999-01-06 | 2010-03-02 | University Of Southern California | Metodo y composicion para la inhibicion de la angiogenesis. |
| CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| HK1044334A1 (zh) | 1999-02-01 | 2002-10-18 | Cv治疗公司 | 依赖细胞周期蛋白的激酶2和IκB-α的嘌呤抑制剂 |
| FR2790702B1 (fr) | 1999-03-08 | 2001-07-20 | Sidel Sa | Unite de moulage et machine d'extrusion-soufflage munie d'une telle unite |
| US6174875B1 (en) | 1999-04-01 | 2001-01-16 | University Of Pittsburgh | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke |
| WO2000068230A1 (en) | 1999-05-05 | 2000-11-16 | Darwin Discovery Limited | 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors |
| US6660845B1 (en) | 1999-11-23 | 2003-12-09 | Epoch Biosciences, Inc. | Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof |
| CO5271715A1 (es) | 1999-12-21 | 2003-04-30 | Sugen Inc | 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa |
| IL150594A0 (en) | 2000-01-07 | 2003-02-12 | Ustav Ex Botan Adademie Ved Ce | Purine derivatives, process for their preparation and use |
| CA2429196A1 (en) | 2000-03-24 | 2001-10-04 | Duke University | Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
| US6667300B2 (en) * | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| GEP20084317B (en) | 2000-04-25 | 2008-02-25 | Icos Corp | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| AU2001271567A1 (en) | 2000-06-29 | 2002-01-14 | Trustees Of Boston University | Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders |
| ATE526019T1 (de) | 2000-07-28 | 2011-10-15 | Sloan Kettering Inst Cancer | Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen |
| US6613089B1 (en) | 2000-10-25 | 2003-09-02 | Sdgi Holdings, Inc. | Laterally expanding intervertebral fusion device |
| US7439359B2 (en) * | 2000-11-02 | 2008-10-21 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to hsp90 |
| AU2002228772B2 (en) | 2000-11-02 | 2005-12-08 | Sloan Kettering Institute For Cancer Research | Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors |
| GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| GB0100621D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VI |
| GB0100623D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds IV |
| MY141789A (en) * | 2001-01-19 | 2010-06-30 | Lg Chem Investment Ltd | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same. |
| CA2440809A1 (en) | 2001-03-01 | 2002-09-12 | Conforma Therapeutics Corp. | Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors |
| CA2377054C (en) * | 2001-03-16 | 2006-09-05 | Susan M. Boyetchko | Biocontrol of weeds using pseudomonas compositions |
| US7157465B2 (en) | 2001-04-17 | 2007-01-02 | Dainippon Simitomo Pharma Co., Ltd. | Adenine derivatives |
| US20020156277A1 (en) * | 2001-04-20 | 2002-10-24 | Fick David B. | Synthesis and methods of use of purine analogues and derivatives |
| US20030022864A1 (en) * | 2001-04-24 | 2003-01-30 | Ishaq Khalid S. | 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| WO2002094196A2 (en) | 2001-05-23 | 2002-11-28 | Sloan Kettering Institute For Cancer Research | Method of treatment for cancers associated with elevated |
| PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| EP1478322A4 (en) | 2001-06-22 | 2007-08-08 | Pharmasset Ltd | Beta 2'-OR 3'-HALONUCLEOSIDE |
| DE60205376T2 (de) | 2001-06-27 | 2006-04-06 | Cyclacel Ltd. | 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten |
| US6962991B2 (en) * | 2001-09-12 | 2005-11-08 | Epoch Biosciences, Inc. | Process for the synthesis of pyrazolopyrimidines |
| CA2460498A1 (en) | 2001-09-24 | 2003-04-03 | Conforma Therapeutics Corporation | Process for preparing 17-allyl amino geldanamycin (17-aag) and other ansamycins |
| CN100350968C (zh) | 2001-09-24 | 2007-11-28 | 皇家创新有限公司 | 饮食行为的改进 |
| JP2003113181A (ja) | 2001-10-04 | 2003-04-18 | Sumika Fine Chemicals Co Ltd | ６−ハロプリンの製造方法 |
| DE10152275A1 (de) | 2001-10-23 | 2003-04-30 | Bayer Ag | Verfahren zur Elektrolyse von wässrigen Lösungen aus Chlorwasserstoff |
| WO2003037860A2 (en) | 2001-10-30 | 2003-05-08 | Conforma Therapeutics Corporation | Purine analogs having hsp90-inhibiting activity |
| EP1450784A4 (en) * | 2001-11-09 | 2005-02-09 | Conforma Therapeutics Corp | HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE |
| AU2002364566B2 (en) | 2001-12-12 | 2009-03-26 | Conforma Therapeutics Corporation | Assays and implements for determining and modulating HSP90 binding activity |
| WO2003066005A2 (en) | 2002-02-08 | 2003-08-14 | Conforma Therapeutics Corporation | Ansamycins having improved pharmacological and biological properties |
| JP2004018453A (ja) | 2002-06-14 | 2004-01-22 | Sumika Fine Chemicals Co Ltd | アルキニルプリン化合物およびその製造方法 |
| US7332486B2 (en) | 2002-08-08 | 2008-02-19 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
| GB0219746D0 (en) * | 2002-08-23 | 2002-10-02 | Inst Of Ex Botany Ascr | Azapurine derivatives |
| AU2003267145A1 (en) * | 2002-09-13 | 2004-04-30 | Irm, Llc | Highly specific modulators of gtpases for target validation |
| RU2005108601A (ru) | 2002-09-26 | 2006-01-20 | Эл Джи Лайф Сайенсиз Лтд. (Kr) | (+)-транс-изомеры(1-фосфонометокси-2-алкилциклопропил)метилнуклеозидные производные, способ получения их стереоизомеров и применение указанных соединений в качестве противовирусных средств |
| US7601694B2 (en) * | 2003-02-20 | 2009-10-13 | New York University | CLK-peptide and SLK-peptide |
| EP1781659B1 (en) * | 2003-07-16 | 2008-11-05 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| AU2004260738B2 (en) * | 2003-07-16 | 2009-07-16 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| US20060252729A1 (en) | 2003-07-30 | 2006-11-09 | Krawczyk Steven H | Nucleobase phosphonate analogs for antiviral treatment |
| WO2005016348A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
| US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
| MXPA06002997A (es) | 2003-09-18 | 2007-02-08 | Conforma Therapeutics Corp | Novedosos compuestos heterociclicos como inhibidores- hsp90. |
| WO2006009245A1 (ja) * | 2004-07-23 | 2006-01-26 | Tanabe Seiyaku Co., Ltd. | 含窒素縮合二環式化合物 |
| WO2007035963A2 (en) * | 2005-09-23 | 2007-03-29 | Conforma Therapeutics Corporation | Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors |
| TWI640539B (zh) | 2015-03-13 | 2018-11-11 | 朱寶麒 | 鋅結合之麩胺基硫轉移酶與金屬硫蛋白融合蛋白 |
-
2004
- 2004-09-20 MX MXPA06002997A patent/MXPA06002997A/es active IP Right Grant
- 2004-09-20 AU AU2004274507A patent/AU2004274507B2/en not_active Ceased
- 2004-09-20 NZ NZ546611A patent/NZ546611A/en not_active IP Right Cessation
- 2004-09-20 CA CA002539548A patent/CA2539548A1/en not_active Abandoned
- 2004-09-20 EA EA200600594A patent/EA010160B1/ru not_active IP Right Cessation
- 2004-09-20 BR BRPI0414533-0A patent/BRPI0414533A/pt not_active IP Right Cessation
- 2004-09-20 JP JP2006527162A patent/JP2007505933A/ja not_active Ceased
- 2004-09-20 US US10/946,645 patent/US7138401B2/en not_active Expired - Lifetime
- 2004-09-20 CN CN2010101575972A patent/CN101906106A/zh active Pending
- 2004-09-20 KR KR1020067007478A patent/KR20060070572A/ko not_active Ceased
- 2004-09-20 US US10/946,637 patent/US7148228B2/en not_active Expired - Lifetime
- 2004-09-20 EP EP04788954A patent/EP1670802A4/en not_active Withdrawn
- 2004-09-20 EP EP09157018A patent/EP2145888A1/en not_active Withdrawn
- 2004-09-20 US US10/945,851 patent/US7138402B2/en not_active Expired - Lifetime
- 2004-09-20 WO PCT/US2004/031248 patent/WO2005028434A2/en not_active Ceased
- 2004-09-20 US US10/946,628 patent/US7129244B2/en not_active Expired - Lifetime
-
2006
- 2006-03-16 IL IL174375A patent/IL174375A0/en unknown
- 2006-03-27 NO NO20061396A patent/NO20061396L/no not_active Application Discontinuation
- 2006-09-12 US US11/531,218 patent/US20070173483A1/en not_active Abandoned
- 2006-09-12 US US11/531,221 patent/US20070185064A1/en not_active Abandoned
- 2006-09-29 US US11/537,017 patent/US20070111997A1/en not_active Abandoned
- 2006-09-29 US US11/537,002 patent/US20070111996A1/en not_active Abandoned
-
2010
- 2010-06-30 AU AU2010202750A patent/AU2010202750B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US7129244B2 (en) | 2006-10-31 |
| EA010160B1 (ru) | 2008-06-30 |
| KR20060070572A (ko) | 2006-06-23 |
| AU2010202750B2 (en) | 2011-09-01 |
| EP1670802A2 (en) | 2006-06-21 |
| WO2005028434A3 (en) | 2006-03-23 |
| US7138402B2 (en) | 2006-11-21 |
| US20050113340A1 (en) | 2005-05-26 |
| BRPI0414533A (pt) | 2006-11-07 |
| US20070111996A1 (en) | 2007-05-17 |
| MXPA06002997A (es) | 2007-02-08 |
| US20050107343A1 (en) | 2005-05-19 |
| EA200600594A1 (ru) | 2006-10-27 |
| EP2145888A1 (en) | 2010-01-20 |
| US7138401B2 (en) | 2006-11-21 |
| US20050113339A1 (en) | 2005-05-26 |
| JP2007505933A (ja) | 2007-03-15 |
| CA2539548A1 (en) | 2005-03-31 |
| AU2010202750A1 (en) | 2010-07-22 |
| US20050119282A1 (en) | 2005-06-02 |
| US20070173483A1 (en) | 2007-07-26 |
| US20070111997A1 (en) | 2007-05-17 |
| AU2004274507B2 (en) | 2010-08-19 |
| AU2004274507A1 (en) | 2005-03-31 |
| EP1670802A4 (en) | 2010-07-07 |
| US20070185064A1 (en) | 2007-08-09 |
| NZ546611A (en) | 2010-02-26 |
| NO20061396L (no) | 2006-06-16 |
| WO2005028434A2 (en) | 2005-03-31 |
| CN101906106A (zh) | 2010-12-08 |
| US7148228B2 (en) | 2006-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL174375A0 (en) | Novel heterocyclic compounds as hsp90-inhibitors | |
| IL209082A0 (en) | Fushed heterocyclic compounds | |
| GB0308114D0 (en) | Novel compounds | |
| GB0324159D0 (en) | Novel compounds | |
| GB0308186D0 (en) | Novel compounds | |
| GB0304424D0 (en) | Novel compounds | |
| GB0321473D0 (en) | Novel compounds | |
| EP1596860A4 (en) | NEW CONNECTIONS | |
| GB0313678D0 (en) | Novel compounds | |
| EP1648885A4 (en) | NEW CONNECTIONS | |
| ZA200700162B (en) | Novel heterocyclic compounds | |
| GB0305426D0 (en) | Novel compounds | |
| GB0310979D0 (en) | Novel compounds | |
| GB0302546D0 (en) | Novel compounds | |
| GB0302431D0 (en) | Novel compounds | |
| GB0304809D0 (en) | Novel compounds | |
| GB0324335D0 (en) | Novel compounds | |
| GB0310962D0 (en) | Novel compounds | |
| HK1089770A (en) | Novel heterocyclic compounds as hsp90-inhibitors | |
| GB0305877D0 (en) | Immunosuppresant heterocyclic compounds | |
| GB0322154D0 (en) | Novel compounds | |
| GB0301591D0 (en) | Novel compounds | |
| GB0316291D0 (en) | Novel compounds | |
| GB0323109D0 (en) | Novel compounds | |
| GB0315519D0 (en) | Novel compounds |